Chinese Language Podcast: 集采, ADC交易, 基因编辑出口和中国生物制药内在矛盾
Hot topics discussed range from ADC deals and VBP to the China biotech paradox
Recent major ADC deals, volume-based procurement (Jicai), China’s plan to ban gene-editing technology exports and the biotech paradox in China are the main topics for this new China Biotech Hot Topic podcast. Brian Yang and Dexter Yan discuss key aspects to watch and the implications for major players as well as the wider pharma sector.
You may also be interested in...
Last December, China's Akeso struck a major agreement worth up to $5bn with Summit Therapeutics, which set a new record in terms of total deal value for a single asset in the Chinese biopharma sector. Akeso founder and CEO Michelle Xia is now planning to pursue a more independent path in taking the firm global.
After inking recent jumbo licensing deals with Merck & Co., Kelun sheds more light on a partnership that traces back to 2020. The Chinese generics-focused firm also elaborates on the design rationale behind its antibody-drug conjugate programs, including the potential competitive benefits of its asset targeting Claudin 18.2.
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.